Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans

Hepatology

Volumn 61, Issue 5, 2015, Pages 1495-1502

  Molnar, Miklos Z ^a   Alhourani, Hazem M ^a   Wall, Barry M ^b   Lu, Jun L ^a   Streja, Elani ^c   Kalantar Zadeh, Kamyar ^c   Kovesdy, Csaba P ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEPATITIS C; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; VETERAN; CHRONIC HEPATITIS C; COMPLICATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; UNITED STATES; VETERANS HEALTH;

COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; UNITED STATES; VETERANS; VETERANS HEALTH;

EID: 84928215082     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27664     Document Type: Article

References (36)

1. World Health Organization. Hepatitis C: fact sheet no. 164. Geneva, Switzerland: World Health Organization; 2014.
2. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-2170.
3. Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2006;17:1168-1174.
4. Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int 2005;67:285-290.
5. Fabrizi F, Martin P, Dixit V, Messa P. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012;7:549-557.
6. Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis 2013;61:623-637.
7. Moe SM, Pampalone AJ, Ofner S, Rosenman M, Teal E, Hui SL. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis 2008;51:885-892.
8. Asrani SK, Buchanan P, Pinsky B, Rey LR, Schnitzler M, Kanwal F. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol 2010;8:79-84.
9. Satapathy SK, Lingisetty CS, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int 2012;6:369-378.
10. Chen YC, Chiou WY, Hung SK, Su YC, Hwang SJ. Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan. BMC Nephrol 2013;14:187.
11. Su FH, Su CT, Chang SN, Chen PC, Sung FC, Lin CC, et al. Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis 2012;60:553-560.
12. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007;167:1271-1276.
13. Lee JJ, Lin MY, Yang YH, Lu SN, Chen HC, Hwang SJ. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis 2010;56:23-31.
14. Lee JJ, Lin MY, Chang JS, Hung CC, Chang JM, Chen HC, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One 2014;9:e100790.
15. Crook ED, Penumalee S, Gavini B, Filippova K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care 2005;28:2187-2191.
16. Gosmanova EO, Lu JN, Streja E, Cushman WC, Kalantar-Zadeh K, Kovesdy CP. Association of medical treatment non-adherence with all-cause mortality in newly treated hypertensive US veterans. Hypertension 2014;64:951-957.
17. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013;158:825-830.
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
19. Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, et al. ACE inhibitor and angiotensin receptor blocker use and mortality in patients with chronic kidney disease. J Am Coll Cardiol 2014;63:650-658.
20. Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Molnar MZ, et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation 2012;125:677-684.
21. Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Molnar MZ, et al. Outcomes associated with microalbuminuria: effect modification by chronic kidney disease. J Am Coll Cardiol 2013;61:1626-1633.
22. VA Information Resource Center. VIReC Research User Guide. VHA Medical SAS Inpatient Datasets FY2006-2007. Hines, IL: US Department of Veterans Affairs; 2007.
23. VA Information Resource Center. Data Quality Update: race. Hines, IL: US Department of Veterans Affairs; 2009.
24. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:136-150.
25. Arnold NSM, Maynard C, Hynes DM. VIReC Technical Report 2: VA-NDI Mortality Data Merge Project. Hines, IL: US Department of Veterans Affairs; 2006.
26. D'Agostino RB Jr. Propensity scores in cardiovascular research. Circulation 2007;115:2340-2343.
27. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc 1999;94:496-509.
28. Noureddine LA, Usman SA, Yu Z, Moorthi RN, Moe SM. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol 2010;32:311-316.
29. Chen YC, Lin HY, Li CY, Lee MS, Su YC. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int 2014;85:1200-1207.
30. Barsoum RS. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transplant 2007;22:1840-1848.
31. Valli MB, Serafino A, Crema A, Bertolini L, Manzin A, Lanzilli G, et al. Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact. J Med Virol 2006;78:192-201.
32. Ratziu V, Heurtier A, Bonyhay L, Poynard T, Giral P. An unexpected virus-host interaction-the hepatitis C virus-diabetes link. Aliment Pharmacol Ther 2005;22(Suppl. 2):56-60.
33. Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009;4:207-220.
34. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
35. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
36. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370:222-232.